BIOCRYST PHARMACEUTICALS, INC. Advertising Expense
BIOCRYST PHARMACEUTICALS, INC. (BCRX) reported Advertising Expense of $13.82 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AdvertisingExpense · last filed 2026-02-26
- BIOCRYST PHARMACEUTICALS, INC. advertising expense for the quarter ending 2023-06-30 was $3.29M, a 19.66% decline year-over-year.
- BIOCRYST PHARMACEUTICALS, INC. advertising expense for the quarter ending 2023-03-31 was $4.05M, a 1.58% increase year-over-year.
- BIOCRYST PHARMACEUTICALS, INC. advertising expense for the quarter ending 2022-12-31 was $3.34M, a 230.62% increase year-over-year.
- BIOCRYST PHARMACEUTICALS, INC. advertising expense for the quarter ending 2022-09-30 was $3.48M, a 132.98% increase year-over-year.
- BIOCRYST PHARMACEUTICALS, INC. advertising expense for fiscal 2025 was $13.82M, a 1.90% increase from fiscal 2024.
- BIOCRYST PHARMACEUTICALS, INC. advertising expense for fiscal 2024 was $13.57M, a 5.82% decline from fiscal 2023.
- BIOCRYST PHARMACEUTICALS, INC. advertising expense for fiscal 2023 was $14.40M, a 3.27% decline from fiscal 2022.
- BIOCRYST PHARMACEUTICALS, INC. advertising expense for fiscal 2022 was $14.89M, a 161.02% increase from fiscal 2021.
| Period end | Advertising Expense 3 month | Advertising Expense 6 month | Advertising Expense 9 month | Advertising Expense 12 month | Advertising Expense 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | $13.82M 10-K · filed 2026-02-26 | ||||
| 2024-12-31 | $13.57M 10-K · filed 2026-02-26 | ||||
| 2023-12-31 | $14.40M 10-K · filed 2026-02-26 | ||||
| 2023-06-30 | $3.29M 10-Q · filed 2023-08-07 | $7.34M 10-Q · filed 2023-08-07 | $10.67M derived: sum of 3 quarters · filed 2025-02-25 | $14.15M derived: sum of 4 quarters · filed 2025-02-25 | |
| 2023-03-31 | $4.05M 10-Q · filed 2023-05-08 | $7.38M derived: sum of 2 quarters · filed 2025-02-25 | $10.86M derived: sum of 3 quarters · filed 2025-02-25 | $14.95M derived: sum of 4 quarters · filed 2025-02-25 | |
| 2022-12-31 | $3.34M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $6.81M derived: sum of 2 quarters · filed 2025-02-25 | $10.91M derived: sum of 3 quarters · filed 2025-02-25 | $14.89M 10-K · filed 2025-02-25 | |
| 2022-09-30 | $3.48M 10-Q · filed 2022-11-04 | $7.57M derived: sum of 2 quarters · filed 2023-08-07 | $11.55M 10-Q · filed 2022-11-04 | $12.56M derived: sum of 4 quarters · filed 2024-02-27 | |
| 2022-06-30 | $4.09M 10-Q · filed 2023-08-07 | $8.08M 10-Q · filed 2023-08-07 | $9.09M derived: sum of 3 quarters · filed 2024-02-27 | $10.58M derived: sum of 4 quarters · filed 2024-02-27 | |
| 2022-03-31 | $3.98M 10-Q · filed 2023-05-08 | $4.99M derived: sum of 2 quarters · filed 2024-02-27 | $6.49M derived: sum of 3 quarters · filed 2024-02-27 | $8.29M derived: sum of 4 quarters · filed 2024-02-27 | |
| 2021-12-31 | $1.01M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $2.50M derived: sum of 2 quarters · filed 2024-02-27 | $4.30M derived: sum of 3 quarters · filed 2024-02-27 | $5.71M 10-K · filed 2024-02-27 | |
| 2021-09-30 | $1.49M 10-Q · filed 2022-11-04 | $3.29M derived: sum of 2 quarters · filed 2022-11-04 | $4.70M 10-Q · filed 2022-11-04 | $11.26M derived: sum of 4 quarters · filed 2023-02-27 | |
| 2021-06-30 | $1.80M 10-Q · filed 2022-08-05 | $3.20M 10-Q · filed 2022-08-05 | $9.77M derived: sum of 3 quarters · filed 2023-02-27 | $9.77M derived: sum of 4 quarters · filed 2023-02-27 | |
| 2021-03-31 | $1.40M 10-Q · filed 2022-05-09 | $7.97M derived: sum of 2 quarters · filed 2023-02-27 | $7.97M derived: sum of 3 quarters · filed 2023-02-27 | $7.97M derived: sum of 4 quarters · filed 2023-02-27 | |
| 2020-12-31 | $6.57M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $6.57M derived: sum of 2 quarters · filed 2023-02-27 | $6.57M derived: sum of 3 quarters · filed 2023-02-27 | $6.57M 10-K · filed 2023-02-27 | $6.57K 10-K · filed 2021-03-01 |
| 2020-09-30 | $0.00 10-Q · filed 2021-11-04 | $0.00 derived: sum of 2 quarters · filed 2021-11-04 | $0.00 10-Q · filed 2021-11-04 | ||
| 2020-06-30 | $0.00 10-Q · filed 2021-08-09 | $0.00 10-Q · filed 2021-08-09 | |||
| 2019-12-31 | $0.00 10-K · filed 2022-02-28 | ||||
| 2018-12-31 | $0.00 10-K · filed 2021-03-01 | ||||
| 2017-12-31 | $0.00 10-K · filed 2020-03-13 | ||||
| 2016-12-31 | $0.00 10-K · filed 2018-03-12 | ||||
| 2015-12-31 | $103.00K 10-K · filed 2018-03-12 | ||||
| 2014-12-31 | $290.00K 10-K · filed 2017-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |